Atossa Genetics Inc.

NASDAQ: ATOSHealthcare / Diagnostic Substances / USA
2.08-0.0700-3.26%Vol 88 6951Y Perf -5.10%
Aug 21st, 2019 16:00
BID2.09 ASK2.12
Open2.15 Previous Close2.15
Pre-Market2.08 After-Trading-
 -0.07 -3.26%  - -%
Target Price
9.00 
Analyst Rating
Hold 3.00
Potencial %
332.69 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)19 
Earnings Rating
Buy
Price Range Ratio 52wk %
19.42 
Earnings Date
12th Aug 2019

Today's Price Range

2.052.19

52wk Range

0.80007.39

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-2.80%
1 Month
1.96%
3 Months
-25.18%
6 Months
36.84%
1 Year
-5.10%
3 Years
-95.38%
5 Years
-99.38%
10 Years
-

Name / TickerPriceChg.Chg.%
ATOS2.08-0.0700-3.26
AAPL212.642.28001.08
GOOG1 191.258.56000.72
MSFT138.791.53001.11
XOM69.720.69001.00
WFC45.000.32000.72
JNJ131.530.93000.71
FB183.55-0.2600-0.14
GE8.16-0.2200-2.63
JPM107.610.30000.28
Earnings HistoryEstimateReportedSurprise %
Q02 2019--0.80-
Q01 2019--0.62-
Q03 2018-0.48-0.64-33.33
Q02 2018-0.74-2.90-291.89
Q01 2018--0.71-
Q03 2017-3.48-2.0441.38
Q02 2017-5.28-7.68-45.45
Q01 2017--5.40-
Earnings Per EndEstimateRevision %Trend
12/2018 QR-0.65-16.07Negative
12/2018 QR-0.5636.36Positive
12/2019 FY-1.280.00-
12/2020 FY-1.510.00-
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume88 695
Shares Outstanding (in ths.)9 130
Trades Count315
Dollar Volume219 958
Avg. Volume1 596 837
Avg. Weekly Volume54 457
Avg. Monthly Volume118 209
Avg. Quarterly Volume421 972
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (100.00 %)
1 (100.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingHold
3.00
Hold
3.00
Strong Buy
1.00

Atossa Genetics Inc.

Atossa Genetics Inc is a clinical-stage pharmaceutical company operating in the US. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The clinical-Stage Programs of the company includes delivery of therapeutics through microcatheters which delivers a number of therapeutics to the ducts in the breast, the site of the majority of early breast cancers and fulvestrant Delivered through microcatheters which delivers fulvestrant as a potential treatment of ductal carcinoma in-situ (DCIS) and breast cancer. In addition, the company involves in the process of evaluating additional potential indications of endoxifen and other therapeutic candidates to treat breast conditions, including breast cancer.

CEO: Steven C. Quay

Teplephone: +1 206 325-6068

Address: 107 Spring Street, Seattle 98104, WA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

54%46%

Bearish Bullish

35%65%

Bearish Bullish

27%73%

News